Troy C. Sarich
AstraZeneca LP
DCC2 W1-345
1800 Concord Pike
Wilmington
USA
Name/email consistency: high
- Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. Sarich, T.C., Wolzt, M., Eriksson, U.G., Mattsson, C., Schmidt, A., Elg, S., Andersson, M., Wollbratt, M., Fager, G., Gustafsson, D. J. Am. Coll. Cardiol. (2003)
- No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran. Sarich, T.C., Teng, R., Peters, G.R., Wollbratt, M., Homolka, R., Svensson, M., Eriksson, U.G. Clin. Pharmacokinet (2003)
- Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis. Sarich, T.C., Osende, J.I., Eriksson, U.G., Fager, G.B., Eriksson-Lepkowska, M., Ohlsson, L., Carlsson, S., Wåhlander, K., Gustafsson, D., Badimon, J.J. J. Thromb. Haemost. (2003)
- Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects. Sarich, T.C., Eriksson, U.G., Mattsson, C., Wolzt, M., Frison, L., Fager, G., Gustafsson, D. Thromb. Haemost. (2002)